The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Stephenson Harwood

Living Wage
Work 020 7329 4422
Fax 020 7329 7100
Beijing, Dubai, Hong Kong, London, Paris, Piraeus and 4 more

Anthony Clare

Work 020 7809 2326
Stephenson Harwood

Work Department



Anthony is a corporate partner specialising in M&A and corporate finance. He covers a range of sectors, with particular market recognition in life sciences and technology.

Anthony advises on a wide range of corporate matters including M&A (public and private), joint ventures and equity capital markets. He has acted on over 20 IPOs in the London market, with a particular bias towards issuer-side mandates. He is well known in the biotech industry, and serves as the deputy chair of the Babraham Institute, Cambridge – one of Europe’s leading bioscience research institutes.

London: Corporate and commercial

Flotations: small and mid-cap

Within: Flotations: small and mid-cap

Stephenson Harwood has a standout capability in funds-related IPOs, secondary fundraisings (by existing listed funds) and other funds-related matters; Alex Haynes acted for Strand Hanson (as NOMAD and broker) in the £55m AIM IPO of Guernsey-incorporated investment fund CIP Merchant Capital. William Saunders, who is another name to note in this area, advised LXI Reit Plc on its £138m Main Market IPO. Outside of funds-related corporate finance, the firm handles a significant number of high-profile AIM transactions for corporate issuers, NOMADs and brokers. Practice head Tom Nicholls advised Macquarie Capital (Europe) Limited as NOMAD and broker on TruFin Plc's £185m AIM admission. Nicholls also acted for Arden Partners Plc as NOMAD and broker to law firm Gordon Dadds in its AIM listing, which followed a reverse takeover. Another key figure is Anthony Clare, who is advising Acacia Pharma Group Plc on its proposed Initial Global Offering and admission to trading on the regulated market of Euronext Brussels. Recently promoted partner Tom Page and senior associate David Dowding are also recommended.

[back to top]

London: TMT (technology, media and telecoms)

Pharmaceuticals and biotechnology

Within: Pharmaceuticals and biotechnology

The 'excellent', 'very pragmatic' and 'professional' Stephenson Harwood focuses on intellectual property and corporate matters in this space. Corporate partner Andrew Edge jointly heads heads the team and recently advised Novacyt on its dual listing on the London Stock Exchange and Euronext Paris. Another key name on the corporate side is Anthony Clare, who assisted Acacia Pharma with its listing on Euronext Brussels. Team co-head Alexandra Pygall specialises in IP and is 'highly knowledgeable in this field'. For contentious matters, her litigation strategy is 'excellent' and she is also 'highly effective' in mediation. Rob Jacob is another key member of the IP team, with notable strengths in trade mark work. Also recommended is senior associate Eibhlin Vardy, who is experienced in patent litigation.

[back to top]

Back to index

Legal Developments by:
Stephenson Harwood

  • Companies should plan now to minimise their pension protection levy

    The amount that pension schemes have to pay to the Pension Protection Fund (PPF) for the year 2006/07 may have increased by as much as five times the previous year's levy. Employers who ultimately bear the cost of many pension schemes will need to make plans now to ensure the levy payable for the year 2008/09 is kept to a minimum.
    - Stephenson Harwood

Legal Developments in London

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to